Electronic-nomogram-guided micafungin dosing regimen in critically ill patients: A population pharmacokinetic study [0.03%]
MICAFUNGIN的剂量调整指南：电子计算图表指导重症患者MICAFUNGIN的剂量调整：基于药物代谢动力学的群体研究
Jean-Joseph Bendjilali-Sabiani,Ahlem Gammoudi,Matthieu Conseil et al.
Jean-Joseph Bendjilali-Sabiani et al.
Objectives: To develop a population pharmacokinetic model for micafungin and an electronic nomogram to support the selection of the optimal initial dosing regimen. ...
Carbapenemase-producing Acinetobacter baumannii from Spanish hospitals, 2016-2020: Interregional spread of ST2PAS isolates co-harbouring blaOXA-23, blaOXA-66 and armA genes [0.03%]
西班牙医院2016-2020年产碳青霉烯酶的鲍曼不动杆菌：同时携带blaOXA-23、blaOXA-66和armA基因的ST2PAS菌株的跨地区传播
Jared Sotelo,Belén Aracil,Jorge Arca-Suárez et al.
Jared Sotelo et al.
Introduction and aims: Carbapenem-resistant Acinetobacter baumannii (CRAB) poses a serious global threat, prioritized by the World Health Organization for new antibiotic development. The European Centre for Disease Preven...
CSF pharmacokinetics-pharmacodynamics of linezolid in critically brain injured patients, with or without central nervous system healthcare-associated infection. The PK-Pop-LCR Study: A Multicentre Pharmacokinetics and Pharmacodynamics Population Study [0.03%]
利奈唑胺在颅内损伤患者（伴有或不伴有中枢神经系统相关感染）中的脑脊液药代动力学和药效学研究：PK-Pop-LCR 研究是一项多中心群体药代动力学和药效学研究
Claire Dahyot-Fizelier,Alexia Chauzy,Kévin Chalard et al.
Claire Dahyot-Fizelier et al.
Linezolid is an alternative to vancomycin for treating Gram-positive central nervous system (CNS) healthcare-associated infections, but its optimal dosing remains debated. The PK-Pop-LCR prospective population pharmacokinetic/pharmacodynami...
In reply to the letter to editor regarding: "Strain-dependent variability in pharmacodynamic interactions for phage-antibiotic combinations in Pseudomonas aeruginosa" [0.03%]
关于读者来信的回复：“铜绿假单胞菌噬菌体-抗生素联合疗法的菌株依赖性药动学相互作用差异性”
Laura R Baars,Meng Gu,Tingjie Guo et al.
Laura R Baars et al.
Identification of a Novel SHV Beta-Lactamase With a Tetrapeptide Duplication in the Omega Loop and a Resistance Profile Resembling SHV-16 [0.03%]
鉴定一种新的SHVβ内酰胺酶其Omega环含有四肽重复与SHV-16的耐药谱相似
Annelie Müller,Martin A Fischer,Guido Werner et al.
Annelie Müller et al.
Drivers of antimicrobial resistance gene clustering in plasmids: distribution, host clinical relevance, and plasmid mobility [0.03%]
质粒中抗微生物药物耐药基因聚类的驱动因素：分布、宿主临床相关性及质粒移动性
Célia P F Domingues,João S Rebelo,Francisco Dionisio et al.
Célia P F Domingues et al.
Plasmids play a central role in the dissemination of antimicrobial resistance genes (ARGs) through horizontal gene transfer. However, the extent to which different resistance determinants are associated and how these associations vary with ...
Comment on "Aztreonam- avibactam pharmacokinetics during extracorporeal membrane oxygenation support: First insights from a case report"Guanghui [0.03%]
关于“体外膜氧合支持下azes特雷龙胺夫西普兰药代动力学：首例病例报道的见解”
Chen,Haibo Lei,Liang Long et al.
Chen et al.
Impact of an Antimicrobial Stewardship intervention on clinical and economic outcomes in Outpatient Parenteral Antimicrobial Therapy (OPAT) for urinary tract infections: a quasi-experimental study [0.03%]
抗菌药物管理干预对门诊输液抗微生物治疗（OPAT）泌尿道感染的临床和经济结局的影响：准实验性研究
Silvia Gómez-Zorrilla,Rosa Ana Sabaté,Inmaculada López Montesinos et al.
Silvia Gómez-Zorrilla et al.
Introduction: Urinary tract infections (UTIs) are a common indication for Outpatient Parenteral Antimicrobial Therapy (OPAT) and often involved prolonged intravenous (IV) treatments. A theory-informed Antimicrobial Stewar...
Pharmacokinetic and pharmacokinetic/pharmacodynamic (PK/PD) considerations of ceftaroline and ceftobiprole for the treatment of Staphylococcus aureus infections: a systematic review [0.03%]
治疗耐甲氧西林金黄色葡萄球菌感染的头孢洛扎和夫拉西林药代动力学和药物浓度-效应关系(PK/PD)的考量：系统性综述
Camilla Genovese,Marta Colaneri,Enrico Sguazzini et al.
Camilla Genovese et al.
Background: Ceftaroline and ceftobiprole are fifth-generation cephalosporins with activity against methicillin-resistant Staphylococcus aureus. Like other β-lactam antimicrobials, their efficacy correlates with the perce...
Impact of timing of aggressive joint PK/PD target attainment of continuous infusion piperacillin-tazobactam on early clinical response of febrile neutropenia to antimicrobial treatment: insights from a prospective, monocentric, observational study in pediatric hematopoietic stem cell recipients [0.03%]
早期持续性哌拉西林他唑巴坦强力抗菌治疗目标浓度时间对造血干细胞移植发热性中性粒细胞减少患儿临床反应的影响：一项单中心前瞻性观察研究的新发现
Milo Gatti,Davide Leardini,Caterina Campoli et al.
Milo Gatti et al.
Objective: To evaluate the impact of timing of aggressive joint pharmacokinetic/pharmacodynamic (PK/PD) target attainment of continuous infusion (CI) piperacillin-tazobactam on early clinical response in pediatric hematop...